Cuprina Holdings (Cayman) Limited reports developments tied to its biomedical product portfolio for chronic wounds, infertility, medical waste recycling and cosmeceuticals. Company updates focus on MEDIFLY, its medical-grade maggot debridement therapy for chronic wound management, including regulatory classification and regional commercialization steps.
Recurring news also covers product and technology diversification, including IVF media production capabilities in Singapore, iodine-based wound care collaborations, and exclusive licensing rights for high-temperature steam treatment technology used to sterilize, decontaminate and recycle plastic-based medical waste. Cuprina's announcements also include scientific advisory activity, public-company communications, financial results and Nasdaq listing-compliance matters.
Cuprina Holdings (Nasdaq: CUPR) has successfully completed its Initial Public Offering (IPO), raising $12.0 million in gross proceeds through the sale of 3,000,000 Class A Ordinary Shares at $4.00 per share. Trading began on NASDAQ on April 10, 2025, under the symbol 'CUPR'.
The company, focused on chronic wound management and cosmeceuticals, plans to utilize the net proceeds for:
- Market expansion
- R&D activities and product portfolio expansion
- Brand awareness building
- Equipment and infrastructure investment
- Working capital and general corporate purposes
R. F. Lafferty & Co. served as the sole book-running manager for the offering. The company's strategy centers on developing sustainable, nature-derived products for treating chronic wounds, targeting the growing market driven by aging populations and increasing prevalence of diabetes, obesity, and cardiovascular ailments.
Cuprina Holdings (CUPR), a biomedical and biotechnology company focused on chronic wound management and cosmeceuticals, has announced the pricing of its Initial Public Offering (IPO). The company is offering 3,000,000 Class A Ordinary Shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 450,000 shares.
The IPO is expected to generate gross proceeds of $13.80 million (assuming full exercise of the over-allotment option), before deducting underwriting costs and offering expenses. Trading will commence on NASDAQ under the symbol 'CUPR' on April 10, 2025, with the offering scheduled to close on April 11, 2025. R. F. Lafferty & Co. is serving as the sole book-running manager for the offering.